阿替唑单抗
医学
内科学
肿瘤科
癌症
免疫疗法
无容量
作者
Mark A. Socinski,Robert M. Jotte,Federico Cappuzzo,Francesco Orlandi,Daniil Stroyakovskiy,Naoyuki Nogami,Delvys Rodríguez‐Abreu,Denis Moro‐Sibilot,Christian A. Thomas,Fabrice Barlési,Gene Grant Finley,Claudia Kelsch,Anthony Lee,Shelley Coleman,Yu Deng,Yijing Shen,Marcin Kowanetz,Ariel López-Chávez,Alan Sandler,Martin Reck
标识
DOI：10.1056/nejmoa1716948
摘要
The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NSCLC, regardless of PD-L1 expression and EGFR or ALK genetic alteration status. (Funded by F. Hoffmann-La Roche/Genentech; IMpower150 ClinicalTrials.gov number, NCT02366143 .).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
shhoing
GingerF
淡定绮波
VDC
无极微光
YifanWang
哈基米德
不配.
tuanheqi
今天任务完成了吗
简单小鸭子
null
风清扬
neuroQi
mmyhn
ccm
持卿
ccczzz
梅天豪
arizaki7
子车茗
猪猪hero
lll
且慢
皖公网安备34019202002308
